Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3RZ9H)

Drug Name
Vemircopan Drug Info
Synonyms
Vemircopan; Vemircopan [INN]; 2086178-00-7; ACH-5228; ACH-0145228; HN6I4K50QB; 2-Azabicyclo(3.1.0)hexane-3-carboxamide, 2-(2-(3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-; 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-3-methyl-2-pyridinyl)-5-methyl-, (1R,3S,5R)-; VEMIRCOPAN [USAN]; UNII-HN6I4K50QB; CFD-IN-1; ALXN2050; CHEMBL4650325; SCHEMBL18578125; ALXN-2050; BDBM386545; GLXC-25930; US10287301, Compound 485; AKOS040757250; MS-30630; CS-0213583; ALXN2050; ACH 0145228; ACH-5228; (1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H-indazol- 1-yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide; (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo(3.1.0)hexane-3-carboxamide; (1R,3S,5R)-2-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide; (1R,3S,5R)-2-{[3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
Indication
Disease Entry ICD 11 Status REF
Generalized myasthenia gravis 8C60 Phase 2 [1]
IgA nephropathy MF8Y Phase 2 [2]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [3]
Proliferative lupus nephritis 4A40 Phase 2 [2]
Cross-matching ID
PubChem CID
126642840
TTD Drug ID
DM3RZ9H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Complement factor D (CFD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lampalizumab DMA2NYS Geographic retinal atrophy 9B78.9 Phase 3 [5]
ALXN2040 DMLJ18Y Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [6]
ACH-4471 DMLVCZR Anaemia 3A90 Phase 2 [7]
BCX-9930 DMBNC1I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [8]
Anti-Factor D DM8ENKS Age-related macular degeneration 9B75.0 Phase 1/2 [9]
ALXN2080 DMQPZQB Discovery agent N.A. Phase 1 [10]
example 373 [WO2012093101] DMP8A5R Discovery agent N.A. Investigative [11]
HC3-1496 DM1BLCX Autoimmune diabetes 5A10 Investigative [12]
Lampalizumab DMA2NYS Geographic retinal atrophy 9B78.9 Phase 3 [5]
ALXN2040 DMLJ18Y Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [6]
ACH-4471 DMLVCZR Anaemia 3A90 Phase 2 [7]
BCX-9930 DMBNC1I Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [8]
Anti-Factor D DM8ENKS Age-related macular degeneration 9B75.0 Phase 1/2 [9]
ALXN2080 DMQPZQB Discovery agent N.A. Phase 1 [10]
example 373 [WO2012093101] DMP8A5R Discovery agent N.A. Investigative [11]
HC3-1496 DM1BLCX Autoimmune diabetes 5A10 Investigative [12]
⏷ Show the Full List of 16 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement factor D (CFD) TT8D13I CFAD_HUMAN Inhibitor [4]

References

1 ClinicalTrials.gov (NCT05218096) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05097989) A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN). U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04170023) A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy. U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of AstraZeneca
5 In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.
6 Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Dec 1;106(12):3188-3197.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT05116774) A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy. U.S.National Institutes of Health.
9 Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9.
10 Clinical pipeline report, company report or official report of Alexion
11 Factor D Inhibitors for the Treatment of AMD: Patent Highlight. ACS Med Chem Lett. 2012 Aug 27;3(10):781-2.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842).